BeyondSpring to Host Virtual R&D Day on Plinabulin Cancer Strategy and SEED Therapeutics Updates
FLORHAM PARK, N.J., May 3, 2024 - BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company in the clinical stage focused on cancer therapy innovation, has announced it will hold a Research and Development (R&D) Day on May 15, 2024, at 10:00 a.m. ET. The event will highlight the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic agent in combination therapies. Additionally, updates will be provided for SEED Therapeutics, BeyondSpring’s subsidiary.
The R&D Day will include presentations by esteemed Key Opinion Leaders (KOLs) such as Dr. Trevor M. Feinstein from Piedmont Cancer Institute, Dr. Alberto Chiappori from Moffitt Cancer Center, and Dr. Steven Lin from MD Anderson Cancer Center. The discussions will cover several topics:
1. History and Development Strategy of Plinabulin for Cancer: This segment will trace the journey of Plinabulin from its inception to its current status in cancer therapy development.
2. Plinabulin’s Immunomodulatory Activity as a Dendritic Cell Maturation Agent: This presentation will explore Plinabulin’s role in modulating the immune system by targeting dendritic cells, a type of immune cell instrumental in fighting cancer.
3. Unmet Needs After Immune-Checkpoint-Inhibitor Failure: This will address the significant gaps in treatment for patients who do not respond to existing immune-checkpoint inhibitors, and how Plinabulin might offer a solution.
In addition to the expert presentations, the event will feature a management discussion on the technology platform and pipeline updates of SEED Therapeutics, BeyondSpring’s subsidiary. SEED Therapeutics focuses on molecular glue technology in drug discovery and development.
Featured Key Opinion Leaders:
- Dr. Trevor M. Feinstein: A board-certified medical oncologist and hematologist, Dr. Feinstein has been with the Piedmont Cancer Institute since 2011 and serves as the Director of Research at Piedmont Fayette Hospital. His work includes overseeing clinical trials for cancer therapies and contributing to various research committees and publications.
- Dr. Alberto Chiappori: Also board-certified in medical oncology, Dr. Chiappori is a senior member of the Thoracic Oncology Program at Moffitt Cancer Center. He is actively involved in several oncology societies and has a rich background in both clinical practice and research.
- Dr. Steven Lin: A Professor and Physician-Scientist at MD Anderson Cancer Center, Dr. Lin has joint appointments in Radiation Oncology and Experimental Radiation Oncology. His work includes leading clinical trials and research teams focused on improving cancer treatment outcomes through advanced therapies like proton beam therapy and immunotherapy.
About BeyondSpring:
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company dedicated to developing innovative therapies aimed at improving clinical outcomes for patients with high unmet medical needs. Their lead asset, Plinabulin, is being advanced as a direct anti-cancer agent and for the prevention of chemotherapy-induced neutropenia. The company’s pipeline also includes three preclinical immuno-oncology assets. BeyondSpring’s subsidiary, SEED Therapeutics, focuses on a proprietary TPD drug discovery platform and collaborates with Eli Lilly on initial research and development projects.
The R&D Day event will be accessible via a conference call and webinar. The dial-in numbers for the call are 1-877-407-0779 (U.S.) or 1-201-389-0914 (international). For those interested in the webinar, registration is required. An archived replay will be available on BeyondSpring’s website post-event.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
